RCT | Single-Dose VLA1553 Chikungunya vaccine shows high immunogenicity and seems safe

Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial – The Lancet

News Release: First phase 3 trial of a chikungunya vaccine candidate finds it is generally safe and provokes an immune response – The Lancet

Commentary on Twitter

New: First phase 3 trial of a chikungunya vaccine candidate finds it is generally safe and provokes an immune response. https://t.co/YSzV5oxXRc pic.twitter.com/rGL7A5eLAr

— The Lancet (@TheLancet) June 13, 2023